PMID- 26498772
OWN - NLM
STAT- MEDLINE
DCOM- 20160629
LR  - 20220408
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 142
IP  - 3
DP  - 2016 Mar
TI  - Upregulation of nuclear transporter, Kpnbeta1, contributes to accelerated cell 
      proliferation- and cell adhesion-mediated drug resistance (CAM-DR) in diffuse 
      large B-cell lymphoma.
PG  - 561-72
LID - 10.1007/s00432-015-2057-4 [doi]
AB  - BACKGROUND: The Karyopherin proteins are involved in the shuttling of cargo 
      proteins, and certain RNAs, across the nuclear pore complex into and out of the 
      cell nucleus. Karyopherin beta1 (Kpnbeta1) is a member of the Karyopherin beta superfamily 
      of nuclear transport proteins. In addition to the nuclear import function, Kpnbeta1 
      is associated with the occurrence of tumors. This study investigated the 
      expression and biologic function of Kpnbeta1 in diffuse large B-cell lymphoma 
      (DLBCL). METHODS: The prognostic value of Kpnbeta1 expression was evaluated using 
      immunohistochemical staining. The role of Kpnbeta1 on cell proliferation- and cell 
      adhesion-mediated drug resistance (CAM-DR) was also determined. RESULTS: We 
      demonstrated that Kpnbeta1 mRNA and protein expression levels were significantly 
      higher in DLBCL B-cells and DLBCL cell lines than in normal CD19 purified 
      B-cells. Immunohistochemical analysis suggested that the expression of Kpnbeta1 was 
      correlated with Ki-67 (P < 0.001). Kaplan-Meier curve showed that high expression 
      of Kpnbeta1 was significantly associated with shorter overall survival. In addition, 
      Kpnbeta1 was associated with the proliferation of DLBCL cells. Importantly, we found 
      that Kpnbeta1 could interact with p65 and promote CAM-DR via accelerating NF-kappaB 
      activation in DLBCL. CONCLUSIONS: Patients with tumors highly expressing Kpnbeta1 
      have poorer overall survivals. Kpnbeta1 interacts with p65 and enhances CAM-DR.
FAU - He, Song
AU  - He S
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Miao, Xiaobing
AU  - Miao X
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Wu, Yaxun
AU  - Wu Y
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Zhu, Xinghua
AU  - Zhu X
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Miao, Xianjing
AU  - Miao X
AD  - Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, 
      Nantong University, Nantong, 226001, Jiangsu, China.
FAU - Yin, Haibing
AU  - Yin H
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - He, Yunhua
AU  - He Y
AD  - Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, 
      Nantong University, Nantong, 226001, Jiangsu, China.
FAU - Li, Chunsun
AU  - Li C
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Liu, Yushan
AU  - Liu Y
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Lu, Xiaoyun
AU  - Lu X
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Chen, Yali
AU  - Chen Y
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Wang, Yuchan
AU  - Wang Y
AD  - Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, 
      Nantong University, Nantong, 226001, Jiangsu, China. wangyuchannt@126.com.
FAU - Xu, Xiaohong
AU  - Xu X
AD  - Department of Oncology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China. xuxiaohongnantong@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151023
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (KPNB1 protein, human)
RN  - 0 (beta Karyopherins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cell Adhesion/genetics
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*genetics
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lymphoma, Large B-Cell, Diffuse/*genetics/metabolism/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Up-Regulation
MH  - beta Karyopherins/*genetics/metabolism
OTO - NOTNLM
OT  - Cell adhesion-mediated drug resistance (CAM-DR)
OT  - Diffuse large B-cell lymphoma (DLBCL)
OT  - Kpnbeta1
OT  - NF-kappaB p65
OT  - Proliferation
EDAT- 2015/10/27 06:00
MHDA- 2016/06/30 06:00
CRDT- 2015/10/27 06:00
PHST- 2015/05/17 00:00 [received]
PHST- 2015/10/13 00:00 [accepted]
PHST- 2015/10/27 06:00 [entrez]
PHST- 2015/10/27 06:00 [pubmed]
PHST- 2016/06/30 06:00 [medline]
AID - 10.1007/s00432-015-2057-4 [pii]
AID - 10.1007/s00432-015-2057-4 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2016 Mar;142(3):561-72. doi: 10.1007/s00432-015-2057-4. 
      Epub 2015 Oct 23.